When prostate cancer circulates in the bloodstream

Diagnostics

Volumn 5, Issue 4, 2015, Pages 428-474

  Vlaeminck Guillem, Virginie ^a,b  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Circulating biomarker; Circulating tumor cells; Diagnosis; Eexosomes; Extracellular vesicles; Free cell DNA; Metastasis; miRNA; Prostate cancer; Tumor aggressiveness

Indexed keywords

DNA; MICRORNA;

BLOOD; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; EXOSOME; HUMAN; IMMUNOMAGNETIC SEPARATION; LABORATORY TEST; METASTASIS; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE; TUMOR EMBOLISM;

EID: 84994030342     PISSN: None     EISSN: 20754418     Source Type: Journal    
DOI: 10.3390/diagnostics5040428     Document Type: Review

References (221)

1. Butler, T.P.; Gullino, P.M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975, 35, 512-516.
2. Krebs, M.G.; Metcalf, R.L.; Carter, L.; Brady, G.; Blackhall, F.H.; Dive, C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014, 11, 129-144.
3. Miyamoto, D.T.; Sequist, L.V.; Lee, R.J. Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol. 2014, 11, 401-412.
4. Stott, S.L.; Lee, R.J.; Nagrath, S.; Yu, M.; Miyamoto, D.T.; Ulkus, L.; Inserra, E.J.; Ulman, M.; Springer, S.; Nakamura, Z.; et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010, 2, 25-23.
5. Meng, S.; Tripathy, D.; Frenkel, E.P.; Shete, S.; Naftalis, E.Z.; Huth, J.F.; Beitsch, P.D.; Leitch, M.; Hoover, S.; Euhus, D.; et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 2004, 10, 8152-8162.
6. Kang, Y.; Pantel, K. Tumor cell dissemination: Emerging biological insights from animal models and cancer patients. Cancer Cell. 2013, 23, 573-581.
7. Uhr, J.W.; Pantel, K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci. USA 2011, 108, 12396-12400.
8. Joosse, S.A.; Gorges, T.M.; Pantel, K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015, 7, 1-11.
9. Kim, M.Y.; Oskarsson, T.; Acharyya, S.; Nguyen, D.X.; Zhang, X.H.; Norton, L.; Massague, J. Tumor self-seeding by circulating cancer cells. Cell. 2009, 139, 1315-1326.
10. Pantel, K.; Brakenhoff, R.H.; Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008, 8, 329-340.
11. Comen, E.; Norton, L.; Massague, J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011, 8, 369-377.
12. Chaffer, C.L.; Weinberg, R.A. A perspective on cancer cell metastasis. Science. 2011, 331, 1559-1564.
13. Friedlander, T.W.; Ngo, V.T.; Dong, H.; Premasekharan, G.; Weinberg, V.; Doty, S.; Zhao, Q.; Gilbert, E.G.; Ryan, C.J.; Chen, W.T.; et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014, 134, 2284-2293.
14. Armstrong, A.J.; Marengo, M.S.; Oltean, S.; Kemeny, G.; Bitting, R.L.; Turnbull, J.D.; Herold, C.I.; Marcom, P.K.; George, D.J.; Garcia-Blanco, M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9, 997-1007.
15. Chen, C.L.; Mahalingam, D.; Osmulski, P.; Jadhav, R.R.; Wang, C.M.; Leach, R.J.; Chang, T.C.; Weitman, S.D.; Kumar, A.P.; Sun, L.; et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 2013, 73, 813-826.
16. Ocana, O.H.; Corcoles, R.; Fabra, A.; Moreno-Bueno, G.; Acloque, H.; Vega, S.; Barrallo-Gimeno, A.; Cano, A.; Nieto, M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22, 709-724.
17. Tsai, J.H.; Donaher, J.L.; Murphy, D.A.; Chau, S.; Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22, 725-736.
18. Tsuji, T.; Ibaragi, S.; Shima, K.; Hu, M.G.; Katsurano, M.; Sasaki, A.; Hu, G.F. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res.2008, 68, 10377-10386.
19. Celia-Terrassa, T.; Meca-Cortes, O.; Mateo, F.; de Paz, A.M.; Rubio, N.; Arnal-Estape, A.; Ell, B.J.; Bermudo, R.; Diaz, A.; Guerra-Rebollo, M.; et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 2012, 122, 1849-1868.
20. Fidler, I.J.; Kripke, M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197, 893-895.
21. Baccelli, I.; Schneeweiss, A.; Riethdorf, S.; Stenzinger, A.; Schillert, A.; Vogel, V.; Klein, C.; Saini, M.; Bauerle, T.; Wallwiener, M.; et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31, 539-544.
22. Bednarz-Knoll, N.; Alix-Panabieres, C.; Pantel, K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012, 31, 673-687.
23. Tam, W.L.; Weinberg, R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 2013, 19, 1438-1449.
24. Todenhofer, T.; Hennenlotter, J.; Feyerabend, S.; Aufderklamm, S.; Mischinger, J.; Kuhs, U.; Gerber, V.; Fetisch, J.; Schilling, D.; Hauch, S.; et al. Preliminary experience on the use of the adnatest(R) system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res. 2012, 32, 3507-3513.
25. Alix-Panabieres, C.; Pantel, K. Challenges in circulating tumour cell research. Nat. Rev. Cancer 2014, 14, 623-631.
26. Smerage, J.B.; Budd, G.T.; Doyle, G.V.; Brown, M.; Paoletti, C.; Muniz, M.; Miller, M.C.; Repollet, M.I.; Chianese, D.A.; Connelly, M.C.; et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol. Oncol. 2013, 7, 680-692.
27. Douma, S.; van Laar, T.; Zevenhoven, J.; Meuwissen, R.; van Garderen, E.; Peeper, D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430, 1034-1039.
28. Steinert, G.; Scholch, S.; Niemietz, T.; Iwata, N.; Garcia, S.A.; Behrens, B.; Voigt, A.; Kloor, M.; Benner, A.; Bork, U.; et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014, 74, 1694-1704.
29. Fidler, I.J. Metastasis: Guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. J. Natl. Cancer Inst. 1970, 45, 773-782.
30. Liotta, L.A.; Saidel, M.G.; Kleinerman, J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976, 36, 889-894.
31. Carvalho, F.L.; Simons, B.W.; Antonarakis, E.S.; Rasheed, Z.; Douglas, N.; Villegas, D.; Matsui, W.; Berman, D.M. Tumorigenic potential of circulating prostate tumor cells. Oncotarget 2013, 4, 413-421.
32. Wood, D.P., Jr.; Banks, E.R.; Humphreys, S.; McRoberts, J.W.; Rangnekar, V.M. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994, 74, 2533-2540.
33. Melchior, S.W.; Corey, E.; Ellis, W.J.; Ross, A.A.; Layton, T.J.; Oswin, M.M.; Lange, P.H.; Vessella, R.L. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin. Cancer Res.1997, 3, 249-256.
34. Corey, E.; Arfman, E.W.; Oswin, M.M.; Melchior, S.W.; Tindall, D.J.; Young, C.Y.; Ellis, W.J.; Vessella, R.L. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997, 50, 184-188.
35. Grasso, Y.Z.; Gupta, M.K.; Levin, H.S.; Zippe, C.D.; Klein, E.A. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage. Cancer Res.1998, 58, 1456-1459.
36. Ellis, W.J.; Vessella, R.L.; Corey, E.; Arfman, E.W.; Oswin, M.M.; Melchior, S.; Lange, P.H. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J. Urol. 1998, 159, 1134-1138.
37. Wang, Z.P.; Eisenberger, M.A.; Carducci, M.A.; Partin, A.W.; Scher, H.I.; Ts'o, P.O. Identification and characterization of circulating prostate carcinoma cells. Cancer 2000, 88, 2787-2795.
38. Moreno, J.G.; O'Hara, S.M.; Gross, S.; Doyle, G.; Fritsche, H.; Gomella, L.G.; Terstappen, L.W. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001, 58, 386-392.
39. Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.; Uhr, J.W.; Terstappen, L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res.2004, 10, 6897-6904.
40. Shaffer, D.R.; Leversha, M.A.; Danila, D.C.; Lin, O.; Gonzalez-Espinoza, R.; Gu, B.; Anand, A.; Smith, K.; Maslak, P.; Doyle, G.V.; et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res.2007, 13, 2023-2029.
41. Alix-Panabieres, C.; Rebillard, X.; Brouillet, J.P.; Barbotte, E.; Iborra, F.; Segui, B.; Maudelonde, T.; Jolivet-Reynaud, C.; Vendrell, J.P. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin. Chem. 2005, 51, 1538-1541.
42. Paris, P.L.; Kobayashi, Y.; Zhao, Q.; Zeng, W.; Sridharan, S.; Fan, T.; Adler, H.L.; Yera, E.R.; Zarrabi, M.H.; Zucker, S.; et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett. 2009, 277, 164-173.
43. Hong, B.; Zu, Y. Detecting circulating tumor cells: Current challenges and new trends. Theranostics 2013, 3, 377-394.
44. Bitting, R.L.; Boominathan, R.; Rao, C.; Kemeny, G.; Foulk, B.; Garcia-Blanco, M.A.; Connelly, M.; Armstrong, A.J. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 2013, 64, 129-136.
45. Joosse, S.A.; Pantel, K. Biologic challenges in the detection of circulating tumor cells. Cancer Res.2013, 73, 8-11.
46. Jones, M.L.; Siddiqui, J.; Pienta, K.J.; Getzenberg, R.H. Circulating fibroblast-like cells in men with metastatic prostate cancer. Prostate 2013, 73, 176-181.
47. Meye, A.; Bilkenroth, U.; Schmidt, U.; Fussel, S.; Robel, K.; Melchior, A.M.; Blumke, K.; Pinkert, D.; Bartel, F.; Linne, C.; et al. Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion automacs protocol. Int. J. Oncol. 2002, 21, 521-530.
48. Nagrath, S.; Sequist, L.V.; Maheswaran, S.; Bell, D.W.; Irimia, D.; Ulkus, L.; Smith, M.R.; Kwak, E.L.; Digumarthy, S.; Muzikansky, A.; et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450, 1235-1239.
49. Thalgott, M.; Rack, B.; Maurer, T.; Souvatzoglou, M.; Eiber, M.; Kress, V.; Heck, M.M.; Andergassen, U.; Nawroth, R.; Gschwend, J.E.; et al. Detection of circulating tumor cells in different stages of prostate cancer. J. Cancer Res. Clin. Oncol. 2013, 139, 755-763.
50. Resel Folkersma, L.; San Jose Manso, L.; Galante Romo, I.; Moreno Sierra, J.; Olivier Gomez, C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 2012, 80, 1328-1332.
51. Davis, J.W.; Nakanishi, H.; Kumar, V.S.; Bhadkamkar, V.A.; McCormack, R.; Fritsche, H.A.; Handy, B.; Gornet, T.; Babaian, R.J. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: Initial results in early prostate cancer. J. Urol. 2008, 179, 2187-2191.
52. Ellis, W.J.; Pfitzenmaier, J.; Colli, J.; Arfman, E.; Lange, P.H.; Vessella, R.L. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003, 61, 277-281.
53. Chen, B.T.; Loberg, R.D.; Neeley, C.K.; O'Hara, S.M.; Gross, S.; Doyle, G.; Dunn, R.L.; Kalikin, L.M.; Pienta, K.J. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 2005, 65, 616-621.
54. Pfitzenmaier, J.; Ellis, W.J.; Hawley, S.; Arfman, E.W.; Klein, J.R.; Lange, P.H.; Vessella, R.L. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol. Oncol. 2007, 25, 214-220.
55. Stott, S.L.; Hsu, C.H.; Tsukrov, D.I.; Yu, M.; Miyamoto, D.T.; Waltman, B.A.; Rothenberg, S.M.; Shah, A.M.; Smas, M.E.; Korir, G.K.; et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. USA 2010, 107, 18392-18397.
56. Lowes, L.E.; Lock, M.; Rodrigues, G.; D'Souza, D.; Bauman, G.; Ahmad, B.; Venkatesan, V.; Allan, A.L.; Sexton, T. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clin. Transl. Oncol. 2012, 14, 150-156.
57. Pantel, K.; Alix-Panabieres, C. The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2012, 2, 974-975.
58. Danila, D.C.; Heller, G.; Gignac, G.A.; Gonzalez-Espinoza, R.; Anand, A.; Tanaka, E.; Lilja, H.; Schwartz, L.; Larson, S.; Fleisher, M.; et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res.2007, 13, 7053-7058.
59. Strijbos, M.H.; Gratama, J.W.; Schmitz, P.I.; Rao, C.; Onstenk, W.; Doyle, G.V.; Miller, M.C.; de Wit, R.; Terstappen, L.W.; Sleijfer, S. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur. J. Cancer 2010, 46, 2027-2035.
60. Amato, R.J.; Melnikova, V.; Zhang, Y.; Liu, W.; Saxena, S.; Shah, P.K.; Jensen, B.T.; Torres, K.E.; Davis, D.W. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer. Urology 2013, 81, 1303-1307.
61. Goldkorn, A.; Ely, B.; Quinn, D.I.; Tangen, C.M.; Fink, L.M.; Xu, T.; Twardowski, P.; van Veldhuizen, P.J.; Agarwal, N.; Carducci, M.A.; et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2014, 32, 1136-1142.
62. Attard, G.; Swennenhuis, J.F.; Olmos, D.; Reid, A.H.; Vickers, E.; A'Hern, R.; Levink, R.; Coumans, F.; Moreira, J.; Riisnaes, R.; et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009, 69, 2912-2918.
63. Reid, A.H.; Attard, G.; Danila, D.C.; Oommen, N.B.; Olmos, D.; Fong, P.C.; Molife, L.R.; Hunt, J.; Messiou, C.; Parker, C.; et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 2010, 28, 1489-1495.
64. Albino, G.; Vendittelli, F.; Paolillo, C.; Zuppi, C.; Capoluongo, E. Potential usefulness of CTC detection in follow up of prostate cancer patients. A preliminary report obtained by using adnagene platform. Arch. Ital. Urol. Androl. 2013, 85, 164-169.
65. Scher, H.I.; Heller, G.; Molina, A.; Attard, G.; Danila, D.C.; Jia, X.; Peng, W.; Sandhu, S.K.; Olmos, D.; Riisnaes, R.; et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2015, 33, 1348-1355.
66. Okegawa, T.; Itaya, N.; Hara, H.; Tambo, M.; Nutahara, K. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res. 2014, 34, 6705-6710.
67. Okegawa, T.; Nutahara, K.; Higashihara, E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J. Urol. 2010, 17, 466-475.
68. Olmos, D.; Arkenau, H.T.; Ang, J.E.; Ledaki, I.; Attard, G.; Carden, C.P.; Reid, A.H.; A'Hern, R.; Fong, P.C.; Oomen, N.B.; et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann. Oncol. 2009, 20, 27-33.
69. De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res.2008, 14, 6302-6309.
70. Okegawa, T.; Nutahara, K.; Higashihara, E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J. Urol. 2009, 181, 1091-1097.
71. Danila, D.C.; Morris, M.J.; de Bono, J.S.; Ryan, C.J.; Denmeade, S.R.; Smith, M.R.; Taplin, M.E.; Bubley, G.J.; Kheoh, T.; Haqq, C.; et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28, 1496-1501.
72. Garcia, J.A.; Rosenberg, J.E.; Weinberg, V.; Scott, J.; Frohlich, M.; Park, J.W.; Small, E.J. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 2007, 99, 519-524.
73. Moreno, J.G.; Miller, M.C.; Gross, S.; Allard, W.J.; Gomella, L.G.; Terstappen, L.W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005, 65, 713-718.
74. Scher, H.I.; Jia, X.; de Bono, J.S.; Fleisher, M.; Pienta, K.J.; Raghavan, D.; Heller, G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol. 2009, 10, 233-239.
75. Goodman, O.B., Jr.; Fink, L.M.; Symanowski, J.T.; Wong, B.; Grobaski, B.; Pomerantz, D.; Ma, Y.; Ward, D.C.; Vogelzang, N.J. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1904-1913.
76. Coumans, F.A.; Doggen, C.J.; Attard, G.; de Bono, J.S.; Terstappen, L.W. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann. Oncol. 2010, 21, 1851-1857.
77. Lohr, J.G.; Adalsteinsson, V.A.; Cibulskis, K.; Choudhury, A.D.; Rosenberg, M.; Cruz-Gordillo, P.; Francis, J.M.; Zhang, C.Z.; Shalek, A.K.; Satija, R.; et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat. Biotechnol. 2014, 32, 479-484.
78. Magbanua, M.J.; Sosa, E.V.; Scott, J.H.; Simko, J.; Collins, C.; Pinkel, D.; Ryan, C.J.; Park, J.W. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 2012, 12, 78, doi:10.1186/1471-2407-12-78.
79. Cann, G.M.; Gulzar, Z.G.; Cooper, S.; Li, R.; Luo, S.; Tat, M.; Stuart, S.; Schroth, G.; Srinivas, S.; Ronaghi, M.; et al. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS ONE 2012, 7, e49144.
80. Smirnov, D.A.; Zweitzig, D.R.; Foulk, B.W.; Miller, M.C.; Doyle, G.V.; Pienta, K.J.; Meropol, N.J.; Weiner, L.M.; Cohen, S.J.; Moreno, J.G.; et al. Global gene expression profiling of circulating tumor cells. Cancer Res.2005, 65, 4993-4997.
81. Schmidt, H.; DeAngelis, G.; Eltze, E.; Gockel, I.; Semjonow, A.; Brandt, B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res.2006, 66, 8959-8965.
82. Arora, R.; Koch, M.O.; Eble, J.N.; Ulbright, T.M.; Li, L.; Cheng, L. Heterogeneity of gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004, 100, 2362-2366.
83. Gasi Tandefelt, D.; Boormans, J.; Hermans, K.; Trapman, J. ETS fusion genes in prostate cancer. Endocr. Relat. Cancer 2014, 21, R143-R152.
84. Danila, D.C.; Anand, A.; Sung, C.C.; Heller, G.; Leversha, M.A.; Cao, L.; Lilja, H.; Molina, A.; Sawyers, C.L.; Fleisher, M.; et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 2011, 60, 897-904.
85. Mao, X.; Shaw, G.; James, S.Y.; Purkis, P.; Kudahetti, S.C.; Tsigani, T.; Kia, S.; Young, B.D.; Oliver, R.T.; Berney, D.; et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J. Androl. 2008, 10, 467-473.
86. Gao, D.; Vela, I.; Sboner, A.; Iaquinta, P.J.; Karthaus, W.R.; Gopalan, A.; Dowling, C.; Wanjala, J.N.; Undvall, E.A.; Arora, V.K.; et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159, 176-187.
87. Miyamoto, D.T.; Lee, R.J.; Stott, S.L.; Ting, D.T.; Wittner, B.S.; Ulman, M.; Smas, M.E.; Lord, J.B.; Brannigan, B.W.; Trautwein, J.; et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012, 2, 995-1003.
88. Jiang, Y.; Palma, J.F.; Agus, D.B.; Wang, Y.; Gross, M.E. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin. Chem. 2010, 56, 1492-1495.
89. Steinestel, J.; Luedeke, M.; Arndt, A.; Schnoeller, T.J.; Lennerz, J.K.; Wurm, C.; Maier, C.; Cronauer, M.V.; Steinestel, K.; Schrader, A.J. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015, doi:10.18632/oncotarget.3925.
90. Leversha, M.A.; Han, J.; Asgari, Z.; Danila, D.C.; Lin, O.; Gonzalez-Espinoza, R.; Anand, A.; Lilja, H.; Heller, G.; Fleisher, M.; et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res.2009, 15, 2091-2097.
91. Ware, K.E.; Garcia-Blanco, M.A.; Armstrong, A.J.; Dehm, S.M. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr. Relat. Cancer 2014, 21, T87-T103.
92. Antonarakis, E.S.; Lu, C.; Wang, H.; Luber, B.; Nakazawa, M.; Roeser, J.C.; Chen, Y.; Mohammad, T.A.; Chen, Y.; Fedor, H.L.; et al. AR-v7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014, 371, 1028-1038.
93. Hu, R.; Lu, C.; Mostaghel, E.A.; Yegnasubramanian, S.; Gurel, M.; Tannahill, C.; Edwards, J.; Isaacs, W.B.; Nelson, P.S.; Bluemn, E.; et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res.2012, 72, 3457-3462.
94. Kirby, B.J.; Jodari, M.; Loftus, M.S.; Gakhar, G.; Pratt, E.D.; Chanel-Vos, C.; Gleghorn, J.P.; Santana, S.M.; Liu, H.; Smith, J.P.; et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS ONE _2012, 7, e35976.
95. Darshan, M.S.; Loftus, M.S.; Thadani-Mulero, M.; Levy, B.P.; Escuin, D.; Zhou, X.K.; Gjyrezi, A.; Chanel-Vos, C.; Shen, R.; Tagawa, S.T.; et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011, 71, 6019-6029.
96. Thadani-Mulero, M.; Portella, L.; Sun, S.; Sung, M.; Matov, A.; Vessella, R.L.; Corey, E.; Nanus, D.M.; Plymate, S.R.; Giannakakou, P. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res.2014, 74, 2270-2282.
97. Zhang, G.; Liu, X.; Li, J.; Ledet, E.; Alvarez, X.; Qi, Y.; Fu, X.; Sartor, O.; Dong, Y.; Zhang, H. Androgen receptor splice variants circumvent ar blockade by microtubule-targeting agents. Oncotarget 2015, 6, 23358-23371.
98. Antonarakis, E.S.; Lu, C.; Luber, B.; Wang, H.; Chen, Y.; Nakazawa, M.; Nadal, R.; Paller, C.J.; Denmeade, S.R.; Carducci, M.A.; et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015, 1, 582-591.
99. Onstenk, W.; Sieuwerts, A.M.; Kraan, J.; Van, M.; Nieuweboer, A.J.; Mathijssen, R.H.; Hamberg, P.; Meulenbeld, H.J.; de Laere, B.; Dirix, L.Y.; et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-v7 in circulating tumor cells. Eur. Urol. 2015, doi:10.1016/j.eururo.2015.07.007.
100. Nakazawa, M.; Lu, C.; Chen, Y.; Paller, C.J.; Carducci, M.A.; Eisenberger, M.A.; Luo, J.; Antonarakis, E.S. Serial blood-based analysis of AR-v7 in men with advanced prostate cancer. Ann. Oncol. 2015, doi: 10.1093/annonc/mdv282.
101. Cho, E.H.; Wendel, M.; Luttgen, M.; Yoshioka, C.; Marrinucci, D.; Lazar, D.; Schram, E.; Nieva, J.; Bazhenova, L.; Morgan, A.; et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys. Biol. 2012, 9, 016001, doi:10.1088/1478-3975/9/1/016001.
102. Hou, J.M.; Krebs, M.G.; Lancashire, L.; Sloane, R.; Backen, A.; Swain, R.K.; Priest, L.J.; Greystoke, A.; Zhou, C.; Morris, K.; et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 2012, 30, 525-532.
103. Aceto, N.; Bardia, A.; Miyamoto, D.T.; Donaldson, M.C.; Wittner, B.S.; Spencer, J.A.; Yu, M.; Pely, A.; Engstrom, A.; Zhu, H.; et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014, 158, 1110-1122.
104. Al-Mehdi, A.B.; Tozawa, K.; Fisher, A.B.; Shientag, L.; Lee, A.; Muschel, R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat. Med. 2000, 6, 100-102.
105. Glinsky, V.V.; Glinsky, G.V.; Glinskii, O.V.; Huxley, V.H.; Turk, J.R.; Mossine, V.V.; Deutscher, S.L.; Pienta, K.J.; Quinn, T.P. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res.2003, 63, 3805-3811.
106. Kim, H.; Terazono, H.; Nakamura, Y.; Sakai, K.; Hattori, A.; Odaka, M.; Girault, M.; Arao, T.; Nishio, K.; Miyagi, Y.; et al. Development of on-chip multi-imaging flow cytometry for identification of imaging biomarkers of clustered circulating tumor cells. PLoS ONE 2014, 9, e104372.
107. Sarioglu, A.F.; Aceto, N.; Kojic, N.; Donaldson, M.C.; Zeinali, M.; Hamza, B.; Engstrom, A.; Zhu, H.; Sundaresan, T.K.; Miyamoto, D.T.; et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat. Methods 2015, 12, 685-691.
108. Brandt, B.; Junker, R.; Griwatz, C.; Heidl, S.; Brinkmann, O.; Semjonow, A.; Assmann, G.; Zanker, K.S. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res.1996, 56, 4556-4561.
109. Giesing, M.; Driesel, G.; Molitor, D.; Suchy, B. Molecular phenotyping of circulating tumour cells in patients with prostate cancer: Prediction of distant metastases. BJU Int. 2012, 110, E1202-E1211.
110. Yao, X.; Choudhury, A.D.; Yamanaka, Y.J.; Adalsteinsson, V.A.; Gierahn, T.M.; Williamson, C.A.; Lamb, C.R.; Taplin, M.E.; Nakabayashi, M.; Chabot, M.S.; et al. Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr. Biol. 2014, 6, 388-398.
111. Giesing, M.; Suchy, B.; Driesel, G.; Molitor, D. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. BJU Int. +2010, 105, 1000-1010.
112. Divella, R.; Daniele, A.; Abbate, I.; Bellizzi, A.; Savino, E.; Simone, G.; Giannone, G.; Giuliani, F.; Fazio, V.; Gadaleta-Caldarola, G.; et al. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer. Cancer Causes Control 2014, 25, 1531-1541.
113. Lu, L.; Zeng, H.; Gu, X.; Ma, W. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Res. Treat. 2015, 151, 491-500.
114. Psaila, B.; Lyden, D. The metastatic niche: Adapting the foreign soil. Nat. Rev. Cancer 2009, 9, 285-293.
115. Duda, D.G.; Duyverman, A.M.; Kohno, M.; Snuderl, M.; Steller, E.J.; Fukumura, D.; Jain, R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA 2010, 107, 21677-21682.
116. Topal, B.; Roskams, T.; Fevery, J.; Penninckx, F. Aggregated colon cancer cells have a higher metastatic efficiency in the liver compared with nonaggregated cells: An experimental study. J. Surg. Res. 2003, 112, 31-37.
117. Labelle, M.; Begum, S.; Hynes, R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20, 576-590.
118. Friedl, P.; Gilmour, D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2009, 10, 445-457.
119. Minciacchi, V.R.; Freeman, M.R.; Di Vizio, D. Extracellular vesicles in cancer: Exosomes, microvesicles and the emerging role of large oncosomes. Semin. Cell Dev. Biol. 2015, 40, 41-51.
120. Record, M.; Subra, C.; Silvente-Poirot, S.; Poirot, M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 2011, 81, 1171-1182.
121. Rak, J. Extracellular vesicles-Biomarkers and effectors of the cellular interactome in cancer. Front. Pharmacol. 2013, 4, 21, doi:10.3389/fphar.2013.00021.
122. Zomer, A.; Maynard, C.; Verweij, F.J.; Kamermans, A.; Schafer, R.; Beerling, E.; Schiffelers, R.M.; de Wit, E.; Berenguer, J.; Ellenbroek, S.I.; et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 2015, 161, 1046-1057.
123. Luga, V.; Zhang, L.; Viloria-Petit, A.M.; Ogunjimi, A.A.; Inanlou, M.R.; Chiu, E.; Buchanan, M.; Hosein, A.N.; Basik, M.; Wrana, J.L. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012, 151, 1542-1556.
124. Gould, S.J.; Raposo, G. As we wait: Coping with an imperfect nomenclature for extracellular vesicles. J. Extracell. Vesicle 2013, 2, doi:10.3402/jev.v2i0.20389.
125. Kalra, H.; Simpson, R.J.; Ji, H.; Aikawa, E.; Altevogt, P.; Askenase, P.; Bond, V.C.; Borras, F.E.; Breakefield, X.; Budnik, V.; et al. Vesiclepedia: A compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012, 10, e1001450.
126. Ronquist, G.; Brody, I. The prostasome: Its secretion and function in man. Biochim. Biophys. Acta 1985, 822, 203-218.
127. Nawaz, M.; Camussi, G.; Valadi, H.; Nazarenko, I.; Ekstrom, K.; Wang, X.; Principe, S.; Shah, N.; Ashraf, N.M.; Fatima, F.; et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat. Rev. Urol. 2014, 11, 688-701.
128. Drake, R.R.; Kislinger, T. The proteomics of prostate cancer exosomes. Expert Rev. Proteomics 2014, 11, 167-177.
129. Bijnsdorp, I.V.; Geldof, A.A.; Lavaei, M.; Piersma, S.R.; van Moorselaar, R.J.; Jimenez, C.R. Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J. Extracell. Vesicle 2013, 2, doi:10.3402/jev.v2i0.22097.
130. Nilsson, J.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X.O.; Widmark, A. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br. J. Cancer 2009, 100, 1603-1607.
131. Corcoran, C.; Rani, S.; O'Brien, K.; O'Neill, A.; Prencipe, M.; Sheikh, R.; Webb, G.; McDermott, R.; Watson, W.; Crown, J.; et al. Docetaxel-resistance in prostate cancer: Evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE 2012, 7, e50999.
132. Khan, S.; Jutzy, J.M.; Valenzuela, M.M.; Turay, D.; Aspe, J.R.; Ashok, A.; Mirshahidi, S.; Mercola, D.; Lilly, M.B.; Wall, N.R. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE 2012, 7, e46737.
133. Mizutani, K.; Terazawa, R.; Kameyama, K.; Kato, T.; Horie, K.; Tsuchiya, T.; Seike, K.; Ehara, H.; Fujita, Y.; Kawakami, K.; et al. Isolation of prostate cancer-related exosomes. Anticancer Res. 2014, 34, 3419-3423.
134. Tavoosidana, G.; Ronquist, G.; Darmanis, S.; Yan, J.; Carlsson, L.; Wu, D.; Conze, T.; Ek, P.; Semjonow, A.; Eltze, E.; et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 8809-8814.
135. Di Vizio, D.; Kim, J.; Hager, M.H.; Morello, M.; Yang, W.; Lafargue, C.J.; True, L.D.; Rubin, M.A.; Adam, R.M.; Beroukhim, R.; et al. Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res.2009, 69, 5601-5609.
136. Minciacchi, V.R.; You, S.; Spinelli, C.; Morley, S.; Zandian, M.; Aspuria, P.J.; Cavallini, L.; Ciardiello, C.; Reis Sobreiro, M.; Morello, M.; et al. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget 2015, 6, 11327-11341.
137. Morello, M.; Minciacchi, V.R.; de Candia, P.; Yang, J.; Posadas, E.; Kim, H.; Griffiths, D.; Bhowmick, N.; Chung, L.W.; Gandellini, P.; et al. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle 2013, 12, 3526-3536.
138. Fleischhacker, M.; Schmidt, B. Circulating nucleic acids (CNAs) and cancer-A survey. Biochim. Biophys. Acta 2007, 1775, 181-232.
139. Jahr, S.; Hentze, H.; Englisch, S.; Hardt, D.; Fackelmayer, F.O.; Hesch, R.D.; Knippers, R. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res.2001, 61, 1659-1665.
140. Ellinger, J.; Muller, S.C.; Stadler, T.C.; Jung, A.; von Ruecker, A.; Bastian, P.J. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol. Oncol. 2011, 29, 124-129.
141. Delgado, P.O.; Alves, B.C.; Gehrke Fde, S.; Kuniyoshi, R.K.; Wroclavski, M.L.; Del Giglio, A.; Fonseca, F.L. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol. 2013, 34, 983-986.
142. Schwarzenbach, H.; Stoehlmacher, J.; Pantel, K.; Goekkurt, E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann. N. Y. Acad. Sci. 2008, 1137, 190-196.
143. Leon, S.A.; Shapiro, B.; Sklaroff, D.M.; Yaros, M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res.1977, 37, 646-650.
144. Schwarzenbach, H.; Alix-Panabieres, C.; Muller, I.; Letang, N.; Vendrell, J.P.; Rebillard, X.; Pantel, K. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res.2009, 15, 1032-1038.
145. Maheswaran, S.; Sequist, L.V.; Nagrath, S.; Ulkus, L.; Brannigan, B.; Collura, C.V.; Inserra, E.; Diederichs, S.; Iafrate, A.J.; Bell, D.W.; et al. Detection of mutations in egfr in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359, 366-377.
146. Mahon, K.L.; Qu, W.; Devaney, J.; Paul, C.; Castillo, L.; Wykes, R.J.; Chatfield, M.D.; Boyer, M.J.; Stockler, M.R.; Marx, G.; et al. Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br. J. Cancer 2014, 111, 1802-1809.
147. Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224-224, doi:10.1126/scitranslmed.3007094.
148. Klein, C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9, 302-312.
149. Schutz, E.; Akbari, M.R.; Beck, J.; Urnovitz, H.; Zhang, W.W.; Bornemann-Kolatzki, K.; Mitchell, W.M.; Nam, R.K.; Narod, S.A. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin. Chem. 2015, 61, 239-248.
150. Boddy, J.L.; Gal, S.; Malone, P.R.; Shaida, N.; Wainscoat, J.S.; Harris, A.L. The role of cell-free DNA size distribution in the management of prostate cancer. Oncol. Res. 2006, 16, 35-41.
151. Cherepanova, A.V.; Tamkovich, S.N.; Bryzgunova, O.E.; Vlassov, V.V.; Laktionov, P.P. Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann. N. Y. Acad. Sci. 2008, 1137, 218-221.
152. Jung, K.; Stephan, C.; Lewandowski, M.; Klotzek, S.; Jung, M.; Kristiansen, G.; Lein, M.; Loening, S.A.; Schnorr, D. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004, 205, 173-180.
153. Papadopoulou, E.; Davilas, E.; Sotiriou, V.; Georgakopoulos, E.; Georgakopoulou, S.; Koliopanos, A.; Aggelakis, F.; Dardoufas, K.; Agnanti, N.J.; Karydas, I.; et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 2006, 1075, 235-243.
154. Allen, D.; Butt, A.; Cahill, D.; Wheeler, M.; Popert, R.; Swaminathan, R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann. N. Y. Acad. Sci. 2004, 1022, 76-80.
155. Altimari, A.; Grigioni, A.D.; Benedettini, E.; Gabusi, E.; Schiavina, R.; Martinelli, A.; Morselli-Labate, A.M.; Martorana, G.; Grigioni, W.F.; Fiorentino, M. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol. 2008, 129, 756-762.
156. Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Lin, X.; Rogers, C.G.; Mangold, L.A.; Trock, B.; Eisenberger, M.; Partin, A.W.; Nelson, W.G. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin. Cancer Res.2007, 13, 5361-5367.
157. Boddy, J.L.; Gal, S.; Malone, P.R.; Harris, A.L.; Wainscoat, J.S. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin. Cancer Res. 2005, 11, 1394-1399.
158. Bryzgunova, O.E.; Tamkovich, S.N.; Cherepanova, A.V.; Yarmoshchuk, S.V.; Permyakova, V.I.; Anykeeva, O.Y.; Laktionov, P.P. Redistribution of free- and cell-surface-bound DNA in blood of benign and malignant prostate tumor patients. Acta Nat. 2015, 7, 115-118.
159. Chun, F.K.; Muller, I.; Lange, I.; Friedrich, M.G.; Erbersdobler, A.; Karakiewicz, P.I.; Graefen, M.; Pantel, K.; Huland, H.; Schwarzenbach, H. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int. 2006, 98, 544-548.
160. Feng, J.; Gang, F.; Li, X.; Jin, T.; Houbao, H.; Yu, C.; Guorong, L. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int. Urol. Nephrol. 2013, 45, 1023-1028.
161. Gordian, E.; Ramachandran, K.; Reis, I.M.; Manoharan, M.; Soloway, M.S.; Singal, R. Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol. Biomark. Prev. 2010, 19, 1984-1991.
162. Ramachandran, K.; Speer, C.G.; Fiddy, S.; Reis, I.M.; Singal, R. Free circulating DNA as a biomarker of prostate cancer: Comparison of quantitation methods. Anticancer Res. 2013, 33, 4521-4529.
163. Wroclawski, M.L.; Serpa-Neto, A.; Fonseca, F.L.; Castro-Neves-Neto, O.; Pompeo, A.S.; Machado, M.T.; Pompeo, A.C.; del Giglio, A. Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumour Biol. 2013, 34, 2921-2927.
164. Kwee, S.; Song, M.A.; Cheng, I.; Loo, L.; Tiirikainen, M. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin. Transl. Sci. 2012, 5, 65-70.
165. Hanley, R.; Rieger-Christ, K.M.; Canes, D.; Emara, N.R.; Shuber, A.P.; Boynton, K.A.; Libertino, J.A.; Summerhayes, I.C. DNA integrity assay: A plasma-based screening tool for the detection of prostate cancer. Clin. Cancer Res. 2006, 12, 4569-4574.
166. Ellinger, J.; Bastian, P.J.; Haan, K.I.; Heukamp, L.C.; Buettner, R.; Fimmers, R.; Mueller, S.C.; von Ruecker, A. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int. J. Cancer 2008, 122, 138-143.
167. Muller, I.; Urban, K.; Pantel, K.; Schwarzenbach, H. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann. N. Y. Acad. Sci. 2006, 1075, 222-229.
168. Schwarzenbach, H.; Chun, F.K.; Lange, I.; Carpenter, S.; Gottberg, M.; Erbersdobler, A.; Friedrich, M.G.; Huland, H.; Pantel, K. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int. J. Cancer 2007, 120, 1465-1471.
169. Schwarzenbach, H.; Chun, F.K.; Muller, I.; Seidel, C.; Urban, K.; Erbersdobler, A.; Huland, H.; Pantel, K.; Friedrich, M.G. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int. 2008, 102, 253-258.
170. Sunami, E.; Shinozaki, M.; Higano, C.S.; Wollman, R.; Dorff, T.B.; Tucker, S.J.; Martinez, S.R.; Mizuno, R.; Singer, F.R.; Hoon, D.S. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin. Chem. 2009, 55, 559-567.
171. Muller, I.; Beeger, C.; Alix-Panabieres, C.; Rebillard, X.; Pantel, K.; Schwarzenbach, H. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: Potential and technical improvements. Clin. Chem. 2008, 54, 688-696.
172. Azad, A.A.; Volik, S.V.; Wyatt, A.W.; Haegert, A.; Le Bihan, S.; Bell, R.H.; Anderson, S.A.; McConeghy, B.; Shukin, R.; Bazov, J.; et al. Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res.2015, 21, 2315-2324.
173. Salvi, S.; Casadio, V.; Conteduca, V.; Burgio, S.L.; Menna, C.; Bianchi, E.; Rossi, L.; Carretta, E.; Masini, C.; Amadori, D.; et al. Circulating cell-free ar and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br. J. Cancer 2015, 112, 1717-1724.
174. Goessl, C.; Muller, M.; Miller, K. Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis. +2000, 3, S17, doi:10.1038/sj.pcan.4500441.
175. Bastian, P.J.; Palapattu, G.S.; Lin, X.; Yegnasubramanian, S.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. Preoperative serum DNA gstp1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res.2005, 11, 4037-4043.
176. Chuang, C.K.; Chu, D.C.; Tzou, R.D.; Liou, S.I.; Chia, J.H.; Sun, C.F. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev. 2007, 31, 59-63.
177. Ellinger, J.; Haan, K.; Heukamp, L.C.; Kahl, P.; Buttner, R.; Muller, S.C.; von Ruecker, A.; Bastian, P.J. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008, 68, 42-49.
178. Reibenwein, J.; Pils, D.; Horak, P.; Tomicek, B.; Goldner, G.; Worel, N.; Elandt, K.; Krainer, M. Promoter hypermethylation of GSTP1, AR, and 14-3-3s in serum of prostate cancer patients and its clinical relevance. Prostate 2007, 67, 427-432.
179. Roupret, M.; Hupertan, V.; Catto, J.W.; Yates, D.R.; Rehman, I.; Proctor, L.M.; Phillips, J.; Meuth, M.; Cussenot, O.; Hamdy, F.C. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 2008, 122, 952-956.
180. Vis, A.N.; Oomen, M.; Schroder, F.H.; van der Kwast, T.H. Feasibility of assessment of promoter methylation of the CD44 gene in serum of prostate cancer patients. Mol. Urol. 2001, 5, 199-203.
181. Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J. Urol. 2008, 179, 529-534.
182. Ahmed, H.; Cappello, F.; Rodolico, V.; Vasta, G.R. Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: Development and validation of a methylated marker for early diagnosis of prostate cancer. Transl. Oncol. 2009, 2, 146-156.
183. Deligezer, U.; Yaman, F.; Darendeliler, E.; Dizdar, Y.; Holdenrieder, S.; Kovancilar, M.; Dalay, N. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin. Chim. Acta 2010, 411, 1452-1456.
184. Wang, L.; Lin, Y.L.; Li, B.; Wang, Y.Z.; Li, W.P.; Ma, J.G. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer. J. Int. Med. Res. 2014, 42, 1085-1092.
185. Reis, I.M.; Ramachandran, K.; Speer, C.; Gordian, E.; Singal, R. Serum GADD45a methylation is a useful biomarker to distinguish benign vs. malignant prostate disease. Br. J. Cancer 2015, 113, 460-468.
186. Cortese, R.; Kwan, A.; Lalonde, E.; Bryzgunova, O.; Bondar, A.; Wu, Y.; Gordevicius, J.; Park, M.; Oh, G.; Kaminsky, Z.; et al. Epigenetic markers of prostate cancer in plasma circulating DNA. Hum. Mol. Genet. 2012, 21, 3619-3631.
187. Papadopoulou, E.; Davilas, E.; Sotiriou, V.; Koliopanos, A.; Aggelakis, F.; Dardoufas, K.; Agnanti, N.J.; Karydas, I.; Nasioulas, G. Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. Oncol. Res. 2004, 14, 439-445.
188. Bryzgunova, O.E.; Morozkin, E.S.; Yarmoschuk, S.V.; Vlassov, V.V.; Laktionov, P.P. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. N. Y. Acad. Sci. 2008, 1137, 222-225.
189. Barry, K.H.; Moore, L.E.; Liao, L.M.; Huang, W.Y.; Andreotti, G.; Poulin, M.; Berndt, S.I. Prospective study of DNA methylation at line-1 and Alu in peripheral blood and the risk of prostate cancer. Prostate 2015, 75, 1718-1725.
190. Salido-Guadarrama, I.; Romero-Cordoba, S.; Peralta-Zaragoza, O.; Hidalgo-Miranda, A.; Rodriguez-Dorantes, M. microRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. OncoTargets Ther. 2014, 7, 1327-1338.
191. Gallo, A.; Tandon, M.; Alevizos, I.; Illei, G.G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE 2012, 7, e30679.
192. Tabet, F.; Vickers, K.C.; Cuesta Torres, L.F.; Wiese, C.B.; Shoucri, B.M.; Lambert, G.; Catherinet, C.; Prado-Lourenco, L.; Levin, M.G.; Thacker, S.; et al. Hdl-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat. Commun. 2014, 5, 3292, doi:10.1038/ncomms4292.
193. Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. microRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423-433.
194. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogosova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108, 5003-5008.
195. Kim, W.T.; Kim, W.J. microRNAs in prostate cancer. Prostate Int. 2013, 1, 3-9.
196. Jackson, B.L.; Grabowska, A.; Ratan, H.L. MicroRNA in prostate cancer: Functional importance and potential as circulating biomarkers. BMC Cancer 2014, 14, 930, doi:10.1186/1471-2407-14-930.
197. Selth, L.A.; Tilley, W.D.; Butler, L.M. Circulating microRNAs: Macro-utility as markers of prostate cancer? Endocr. Relat. Cancer 2012, 19, R99-R113.
198. Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; Pezzella, F.; Boultwood, J.; Wainscoat, J.S.; et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141, 672-675.
199. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997-1006.
200. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
201. O'Kelly, F.; Marignol, L.; Meunier, A.; Lynch, T.H.; Perry, A.S.; Hollywood, D. microRNAs as putative mediators of treatment response in prostate cancer. Nat. Rev. Urol. 2012, 9, 397-407. 202. Lodes, M.J.; Caraballo, M.; Suciu, D.; Munro, S.; Kumar, A.; Anderson, B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009, 4, e6229.
202. Lodes, M.J.; Caraballo, M.; Suciu, D.; Munro, S.; Kumar, A.; Anderson, B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009, 4, e6229.
203. Moltzahn, F.; Olshen, A.B.; Baehner, L.; Peek, A.; Fong, L.; Stoppler, H.; Simko, J.; Hilton, J.F.; Carroll, P.; Blelloch, R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011, 71, 550-560.
204. Yaman Agaoglu, F.; Kovancilar, M.; Dizdar, Y.; Darendeliler, E.; Holdenrieder, S.; Dalay, N.; Gezer, U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011, 32, 583-588.
205. Gonzales, J.C.; Fink, L.M.; Goodman, O.B., Jr.; Symanowski, J.T.; Vogelzang, N.J.; Ward, D.C. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 2011, 9, 39-45.
206. Zhang, H.L.; Yang, L.F.; Zhu, Y.; Yao, X.D.; Zhang, S.L.; Dai, B.; Zhu, Y.P.; Shen, Y.J.; Shi, G.H.; Ye, D.W. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71, 326-331.
207. Brase, J.C.; Johannes, M.; Schlomm, T.; Falth, M.; Haese, A.; Steuber, T.; Beissbarth, T.; Kuner, R.; Sultmann, H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128, 608-616.
208. Selth, L.A.; Townley, S.; Gillis, J.L.; Ochnik, A.M.; Murti, K.; Macfarlane, R.J.; Chi, K.N.; Marshall, V.R.; Tilley, W.D.; Butler, L.M. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 2012, 131, 652-661.
209. Selth, L.A.; Townley, S.L.; Bert, A.G.; Stricker, P.D.; Sutherland, P.D.; Horvath, L.G.; Goodall, G.J.; Butler, L.M.; Tilley, W.D. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br. J. Cancer 2013, 109, 641-650.
210. Bryant, R.J.; Pawlowski, T.; Catto, J.W.; Marsden, G.; Vessella, R.L.; Rhees, B.; Kuslich, C.; Visakorpi, T.; Hamdy, F.C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106, 768-774.
211. Huang, X.; Yuan, T.; Liang, M.; Du, M.; Xia, S.; Dittmar, R.; Wang, D.; See, W.; Costello, B.A.; Quevedo, F.; et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur. Urol. 2015, 67, 33-41.
212. Nguyen, H.C.; Xie, W.; Yang, M.; Hsieh, C.L.; Drouin, S.; Lee, G.S.; Kantoff, P.W. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013, 73, 346-354.
213. Chen, Z.H.; Zhang, G.L.; Li, H.R.; Luo, J.D.; Li, Z.X.; Chen, G.M.; Yang, J. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012, 72, 1443-1452.
214. Shen, J.; Hruby, G.W.; McKiernan, J.M.; Gurvich, I.; Lipsky, M.J.; Benson, M.C.; Santella, R.M. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012, 72, 1469-1477.
215. Mahn, R.; Heukamp, L.C.; Rogenhofer, S.; von Ruecker, A.; Muller, S.C.; Ellinger, J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011, 77, e1269-e1216.
216. Westermann, A.M.; Schmidt, D.; Holdenrieder, S.; Moritz, R.; Semjonow, A.; Schmidt, M.; Kristiansen, G.; Muller, S.C.; Ellinger, J. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: Results from a prospective multi-center study. Anticancer Res. 2014, 34, 665-669.
217. Kelly, B.D.; Miller, N.; Sweeney, K.J.; Durkan, G.C.; Rogers, E.; Walsh, K.; Kerin, M.J. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J. Clin. Med. 2015, 4, 1369-1379.
218. Mihelich, B.L.; Maranville, J.C.; Nolley, R.; Peehl, D.M.; Nonn, L. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS ONE +2015, 10, e0124245.
219. Lin, H.M.; Castillo, L.; Mahon, K.L.; Chiam, K.; Lee, B.Y.; Nguyen, Q.; Boyer, M.J.; Stockler, M.R.; Pavlakis, N.; Marx, G.; et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br. J. Cancer 2014, 110, 2462-2471.
220. Kachakova, D.; Mitkova, A.; Popov, E.; Popov, I.; Vlahova, A.; Dikov, T.; Christova, S.; Mitev, V.; Slavov, C.; Kaneva, R. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 2015, 34, 189-200.
221. Haldrup, C.; Kosaka, N.; Ochiya, T.; Borre, M.; Hoyer, S.; Orntoft, T.F.; Sorensen, K.D. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv. Transl. Res. +2014, 4, 19-30.